Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Levocarnitine Propionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionyl-Carnitine SCHEMBL3637406 | 1.00 | MEN1 (0.80) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL3639171 | 0.99 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL3039334 | 0.99 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL19617435 | 0.91 | MEN1 (0.90) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL1358526 | 0.91 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL1358528 | 0.91 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL156850 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL464940 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL994714 | 0.89 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.88 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160255866-A1 | NUTRITIONAL SUPPLEMENT | JANKOWITZ STANLEY N (US) | 2016-09-08 | — | — | US | claimed |
| US-9198881-B2 | Equine nutritional supplement | EQUINE NUTRICEUTICALS LLC | 2015-12-01 | — | — | US | claimed |
| EP-2665473-A2 | EQUINE NUTRITIONAL SUPPLEMENT | Equine Nutriceuticals, LLC (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012099980-A2 | EQUINE NUTRITIONAL SUPPLEMENT | EQUINE NUTRICEUTICALS, LLC (US) | 2012-07-26 | — | — | WO | claimed |
| US-20120183521-A1 | EQUINE NUTRITIONAL SUPPLEMENT | EQUINE NUTRICEUTICALS LLC | 2012-07-19 | — | — | US | claimed |
| US-7854939-B2 | Gel useful for the delivery of cosmetic active ingredients | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-21 | — | — | US | claimed |
| EP-2152225-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2009-12-17 | — | — | US | claimed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | claimed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | claimed |
| US-20070072910-A1 | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | NEXGEN PHARMA, INC. | 2007-03-29 | — | — | US | claimed |
| CN-111960959-A | Preparation method of glycine propionyl L-carnitine hydrochloride moisture-proof particles | 辽宁科硕营养科技股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-111960959-A | Preparation method of glycine propionyl L-carnitine hydrochloride moisture-proof particles | 辽宁科硕营养科技股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-111960959-A | Preparation method of glycine propionyl L-carnitine hydrochloride moisture-proof particles | 辽宁科硕营养科技股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10130602-B2 | Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function | LONZA LTD. (CH) | 2018-11-20 | — | — | US | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138393-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-11-20 | — | — | WO | disclosed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20070072910-A1 | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | NEXGEN PHARMA, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279900-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, CUTA | MEN1 3124/4885KMT2A 3957/4885CYP2C19 2896/4885 |
| US-20090312421-A1 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS | SLC25A20, CRAT, UGCG | MEN1 3282/4885KMT2A 3926/4885CYP2C19 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.